Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyper stimulation in women with polycystic ovarian disease undergoing Intracytoplasmic sperm injection (ICSI ).

Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyper stimulation in women with polycystic ovarian disease undergoing ICSI .

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000904774

Enrollment

100

Registered

2013-08-13

Start date

2013-07-15

Completion date

2014-04-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

we study novel approaches in the management of ovarian hyperstimulation in women suffering with Polycystic ovarian disease (PCO) and undergoing Intracytoplasmic sperm injection (ICSI).we compare the effect of intravenous calcium and oral cabergoline on the severity of ovarian hyperstimulation and outcome of ICSI as regard the pregnancy rate and miscarriage rate

Interventions

0.5 mg oral Tablets cabergoline (Dostinex) daily for 8 days from the day of HCG injection. For once in the trial To monitor the adherence to the medication we ask the patient for the drug tablet return.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

-Subfertile women with polycystic ovarian disease -serum FSH within normal limits( 1-12IU /l) -at least 15 follicles or more ,more than 10 mm at the time of HCG administration

Exclusion criteria

-patients need coasting for high risk of OHSS. -patients need cycle cancellation. -severe male infertility requiring testicular sperm extraction.

Outcome results